Costs and outcomes associated with colfosceril versus beractant for the treatment of neonatal respiratory distress syndrome.
Wyble
L
L
Santeiro
M L
ML
D001688:Biological Products; D004338:Drug Combinations; D016527:Drug Costs; D005233:Fatty Alcohols / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D010767:Phosphorylcholine; D011092:Polyethylene Glycols / Q000191:economics / Q000627:therapeutic use*; D011663:Pulmonary Surfactants / Q000191:economics / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000191:economics; D016896:Treatment Outcome
D001688:Biological Products; D004338:Drug Combinations; D005233:Fatty Alcohols; D011663:Pulmonary Surfactants; D010767:Phosphorylcholine; D011092:Polyethylene Glycols; C047049:dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination; C072197:beractant